Stay updated on Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate Clinical Trial
Sign up to get notified when there's something new on the Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate Clinical Trial page.

Latest updates to the Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate Clinical Trial page
- Check3 days agoChange DetectedLocations section now lists District of Columbia and New Jersey as study sites. The revision label is updated to Revision: v3.3.3.SummaryDifference0.3%

- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check32 days agoChange DetectedPublications section wording now states automatic population from PubMed and the page revision is updated to v3.3.2, replacing the previous wording and revision v3.2.0.SummaryDifference0.1%

- Check39 days agoChange DetectedThe top government funding/operating status notice on the study details page has been removed.SummaryDifference0.3%

- Check53 days agoChange DetectedNo significant changes to core content were detected; only minor formatting adjustments observed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check82 days agoChange DetectedMajor update adds a government operations notice and NIH Clinical Center status with a v3.2.0 release; removes a specific resource (Small cell lung carcinoma) from the GARD list and drops the v3.1.0 reference.SummaryDifference2%

- Check89 days agoChange DetectedUpdated the page version from v3.0.2 to v3.1.0; no other content changes detected.SummaryDifference0.0%

Stay in the know with updates to Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate Clinical Trial page.